Haifeng Chen | Chief Executive Officer
Virovek

Haifeng Chen, Chief Executive Officer, Virovek

Dr. Haifeng Chen obtained his Bachelor of Science Degree from Sun Yat-sen University in 1982 and his Master of Science Degree from Sichuan University in 1985. After working in the Cancer Institute of Sun Yat-sen University for four years, he went to Germany in 1989 to pursue his study in the Department of Virology, University of Saarland and obtained his Ph.D. in 1992. In the same year he was awarded the Marion-Merrell-Dow Post-Doctoral Fellowship to perform research on adenovirus replication at the University of Kansas Medical Center in Kansas City, Kansas. In 1996, he joined Cell Genesys, Inc. and continued his postdoctoral work focusing on the development of adenovirus and adeno-associated virus (AAV) as gene therapy vectors. In 1997, he took a Research Scientist position at Genovo, Inc. and developed two AAV production systems, one based on baculovirus and the other based on adenovirus. In 2000, he joined Avigen, Inc. as a research scientist focusing on the development of novel AAV vector production technologies. In June 2005, he joined Asklepois BioPharmaceutical, Inc. as Vice President of Production. In June 2006, Dr. Chen founded his own company, Virovek, to provide AAV vector production services to the academic and biopharmaceutical research communities. Besides providing services, he has invented several novel technologies for large-scale AAV vector production and purification. Under his leadership, Virovek has now developed the capacity to provide purified AAV vectors exceeding 3 x 1016vg per production run. Dr. Chen is currently a member of the editorial board for Molecular Therapy - Methods and Clinical Development, and a committee member of the Viral Gene Transfer Vector Committee of American Society of Gene and Cell Therapy (ASGCT). He is also a member of Society for Neuroscience (SfN) and American Association for Cancer Research (AACR).

Appearances:



Conference Day 1: Thursday 16th May 2019 @ 16:45

BAC-to-AAV: The Technology for Large Scale AAV Manufacturing

  • Current AAV production systems and their challenges
  • First generation system for AAV production in Sf9 cells and its deficiencies
  • Virovek's serum-free "BAC-to-AAV" technology and its advantages
  • Novel three-phase partitioning (TPP) as upstream process for large scale AAV purification
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com